157
Participants
Start Date
July 6, 2022
Primary Completion Date
October 30, 2025
Study Completion Date
November 30, 2026
BGB-24714
administered orally
Paclitaxel
administered intravenously
Carboplatin
administered intravenously
Docetaxel
administered intravenously
Auckland City Hospital, Auckland
National Cancer Center (Korea), IlsandongGu GoyangSi
Gachon University Gil Medical Center, NamdongGu
Next Virginia, Fairfax
Florida Cancer Specialist (Scri) Sarasota, Sarasota
Tennessee Oncology, Pllc Nashville, Nashville
Mary Crowley Cancer Research, Dallas
Intermountain Healthcare, Salt Lake City
University of Washington, Seattle
Shandong Provincial Hospital, Jinan
Shandong Cancer Hospital, Jinan
Chongqing Cancer Hospital, Chongqing
Hunan Cancer Hospital, Changsha
Henan Cancer Hospital, Zhengzhou
Banner Md Anderson Cancer Center, Gilbert
Scri Florida Cancer Specialists North, St. Petersburg
Scri Florida Cancer Specialist East, West Palm Beach
Massachusetts General Hospital, Boston
Barbara Ann Karmanos Cancer Institute, Detroit
Hackensack University Medical Center, Hackensack
Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh
Sanford Cancer Center, Sioux Falls
Avera Cancer Institute, Sioux Falls
University of Texas Southwestern Medical Center, Dallas
The University of Texas Md Anderson Cancer Center (Department Gi Medical Oncology), Houston
Northern Beaches Hospital, Frenchs Forest
Icon Cancer Centre South Brisbane, South Brisbane
Princess Alexandra Hospital, Woolloongabba
Austin Health, Heidelberg
Peter Maccallum Cancer Centre, Melbourne
Sunshine Hospital, St Albans
Samsung Medical Center, GangnamGu
Severance Hospital Yonsei University Health System, SeodaemunGu
Asan Medical Center, SongpaGu
Lead Sponsor
BeiGene
INDUSTRY